H.C. Wainwright analyst Debjit Chattopadhyay says Voyager Therapeutics' (VYGR) licensing deal with Neurocrine Biosciences (NBIX) eliminates the need for "vulture financing, especially with the stock languishing near its 52-week lows prior to the announcement." With pro forma cash of $344M, Voyager's "rejuvenated" balance sheet should fund anticipated investments into pipeline augmentation well into 2022, Chattopadhyay tells investors in a research note. While Voyager shares lack near-term clinical milestones, the augmented balance sheet, new management, and multiple new new drug filings during 2019 should bring "this neurology focused biotech back into investors' radar," adds the analyst. He reiterates a Buy rating on the shares with a $21 price target.